Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Bridgebio Pharma Inc (NQ: BBIO ) 24.94 +0.46 (+1.88%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Bridgebio Pharma Inc < Previous 1 2 3 4 Next > BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events Today 18:00 EDT From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA September 17, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program September 10, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH) September 10, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) September 06, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BRIDGEBIO PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates BridgeBio Pharma, Inc. - BBIO August 30, 2024 From Kahn Swick & Foti, LLC Via Business Wire BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension August 30, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024 August 29, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma to Participate in September Investor Events August 28, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence August 26, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia August 19, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) August 08, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update August 01, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer July 23, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) July 05, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) June 18, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings June 12, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) June 10, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference June 06, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings June 05, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia June 04, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024 June 03, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) May 29, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting May 24, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) May 15, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024 May 14, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified May 13, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update May 02, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline May 02, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) April 10, 2024 From BridgeBio Pharma, Inc. Via GlobeNewswire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.